potent, selective CECR2 bromodomain inh.

cell permeable tool compound

from HTS + SBDD on ATAD2, CECR2 model

J. Med. Chem., May 28, 2020

GlaxoSmithKline, Stevenage, UK

Structure of GSK232

GSK232 is a highly selective cell-penetrant inhibitor of the non-BET CECR2 bromodomain with >500-fold selectivity over BET-family bromodomains identified during a campaign to find selective inhibitors of the bromodomain…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: